FDA — authorised 25 August 2017
- Application: BLA761058
- Marketing authorisation holder: BOEHRINGER INGELHEIM
- Local brand name: CYLTEZO
- Indication: INJECTABLE — INJECTION
- Status: approved
🇺🇸 CYLTEZO in United States
FDA authorised CYLTEZO on 25 August 2017
Marketing authorisation
CYLTEZO in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United States
Frequently asked questions
Is CYLTEZO approved in United States?
Yes. FDA authorised it on 25 August 2017.
Who is the marketing authorisation holder for CYLTEZO in United States?
BOEHRINGER INGELHEIM holds the US marketing authorisation.